The FASEB Journal · 2012 · 103 citations · 50 references
Life SciencesImmunologyPharmacologyCell SignalingImmunopharmacologyInflammationAnti-inflammatory PharmacologyInflammatory Disease PharmacotherapyInflammatory MediatorsInflammatory ProcessesInflammatory SignalingMast Cell ActivationAnti-inflammatory TherapeuticsCalcium Signaling In InflammationCollagen-induced ArthritisMacrophage Activation SignalingMacrophage-mediated InflammationMast Cell Degranulation InhibitionMonocyte-derived MacrophagesProinflammatory Mediators
ABSTRACT Multiple serine proteases exert proinflammatory actions by signaling through protease‐activated receptor‐2 (PAR2) on the cell surface. Although inhibitors of individual proteases are anti‐inflammatory, we sought to discover whether the first potent antagonist of their common target PAR2 might be beneficial in treating chronic arthritis‐like inflammatory disease. Using a fluorescence assay, a novel compound, GB88, was shown to antagonize PAR2‐induced intracellular Ca 2+ release in human monocyte‐derived macrophages, being 1000 times more potent than a control compound, ENMD‐1068 (IC 50 1.6±0.5 μM vs. 1.2±0.4 mM, respectively). In Wistar rats, GB88 was orally bioavailable ( F =55%, T max 4 h, C max 1.7 μM, 10 mg/kg). GB88 inhibited the acute paw edema induced in Wistar rats by intraplantar λ‐carrageenan or PAR2 agonists 2‐furoyl‐LIGRLO‐NH 2 or mast cell β‐tryptase, without inhibiting proteolytic activity of tryptase in vitro. In the chronic collagen‐induced model of arthritis in rats, GB88 (10 mg/kg) was disease modifying and ameliorated pathological and histopathological changes (edema, pannus formation, synovial hyperplasia, collagen degradation, macrophage invasion, mast cell degranulation) compared to untreated arthritic controls. The results suggest that an orally active PAR2 antagonist is effective in treating chronic arthritis in rats through inhibiting macrophage infiltration, mast cell degranulation, and β‐tryptase‐PAR2 signaling in joint inflammation.—Lohman, R.‐J., Cotterell, A. J., Barry, G. D., Liu, L., Suen, J. Y., Vesey, D. A., Fairlie, D. P. An antagonist of human protease activated receptor‐2 attenuates PAR2 signaling, macrophage activation, mast cell degranulation, and collagen‐induced arthritis in rats. FASEB J. 26, 2877–2887 (2012). www.fasebj.org
50
Proteinase-activated Receptors
Scott R. Macfarlane, Michael J. Seatter, Toru Kanke et al. · 2006 · 1.1K citations
Mast Cells: A Cellular Link Between Autoantibodies and Inflammatory Arthritis
David M. Lee, Daniel S. Friend, Michael F. Gurish et al. · Science · 2002 · 744 citations
Life Sciences, Immunology, Pathology +17
Essential role for proteinase-activated receptor-2 in arthritis
William R. Ferrell, John C. Lockhart, Elizabeth B. Kelso et al. · Journal of Clinical Investigation · 2003 · 335 citations · Full text
Medicine, Immunology, Pharmacology +17